Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Bright Peak Therapeutics AG currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. This portfolio of 3 pending actions reflects the company's active efforts to secure patent rights for its biotechnological and pharmaceutical innovations. The focus on Biotechnology & Pharmaceuticals is central to its current intellectual property strategy, aiming to protect its specialized therapeutic research.
The prosecution is distributed among 3 distinct examiners and 3 distinct art units. Since there are 3 pending office actions and 3 distinct examiners, each case is being handled by a different individual at the patent office. The fact that there are also 3 distinct art units involved means that every single pending application is being reviewed in a different specialized department, requiring the company to navigate various departmental standards and guidelines.
GODDARD, LAURA B is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Because the busiest examiner pending count is 1 and there are 3 total pending office actions, the workload is evenly spread across all 3 distinct examiners. This highly distributed structure across 3 distinct art units requires the company to navigate three different sets of examiner tendencies and departmental standards simultaneously to advance its patent objectives.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| GURLEY, JAMI MICHELLE | 1 | 53.3% | +16.1% |
| CHATTIN, AMY MARIE | 1 | 73.6% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18113399 | ACTIVATABLE IL-18 POLYPEPTIDES | CHATTIN, AMY MARIE | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18113399 | ACTIVATABLE IL-18 POLYPEPTIDES | CHATTIN, AMY MARIE | 5d overdue |
| 18113409 | MODIFIED IL-18 POLYPEPTIDES | GURLEY, JAMI MICHELLE | 22d |
| 19569819 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1647 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19569819 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | GODDARD, LAURA B | 1642 | §103§112DP | Non-Final OA | — | Pending | Mar 17, 2026 |
| 18113409 | MODIFIED IL-18 POLYPEPTIDES | GURLEY, JAMI MICHELLE | 1647 | §103Other | Final Rejection | 22d | Pending | Feb 23, 2023 |
| 18113399 | ACTIVATABLE IL-18 POLYPEPTIDES | CHATTIN, AMY MARIE | 1643 | §102§103 | Final Rejection | 5d overdue | Pending | Feb 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial